Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
Tandem Diabetes Care president and CEO John F. Sheridan reported equity compensation activity tied to restricted stock units (RSUs). On February 17, he acquired common shares through the exercise or conversion of RSUs, while a portion of the vested shares was withheld to cover tax obligations.
The filing shows tax-withholding dispositions of 1,963 and 2,400 common shares at $18.95 per share, with a footnote clarifying these were shares retained by the company to satisfy taxes and that no shares were sold on the open market.
Tandem Diabetes Care EVP & CFO Leigh Vosseller reported the vesting and exercise of restricted stock units into common stock, along with related tax withholding transactions. On February 17, 2026, 1,503 and 1,495 restricted stock units were converted into common shares at $0.00 per share. To cover tax obligations, 619 and 616 common shares were withheld at $18.95 per share, and a footnote states that no shares were sold. Following these transactions, Vosseller held 39,411 common shares directly and 25,580 common shares indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care executive vice president and chief legal officer Shannon Marie Hansen reported equity award activity involving restricted stock units and common stock. On February 17, 2026, several RSU awards vested and were converted into common shares at no exercise price.
Across these transactions, Hansen acquired common stock through derivative exercises coded "M" and had portions of the newly delivered shares withheld, coded "F", to cover tax obligations at $18.95 per share, with a footnote stating no shares were sold in the market. Following these movements, she directly held 23,276 shares of common stock. An additional 1,935 shares were reported as held indirectly through the Shannon M. Hansen Trust, where she serves as trustee.
Tandem Diabetes Care files its annual report describing a global insulin-delivery business built around its X2 and Tandem Mobi pumps, both using Control‑IQ+ automated insulin delivery technology. The company serves nearly 500,000 people with insulin‑dependent diabetes across more than 25 countries and is expanding from type 1 into intensive‑insulin type 2 therapy.
Tandem highlights a shift to a multi‑channel reimbursement model in the U.S., adding pharmacy benefits alongside traditional durable medical equipment coverage. The filing outlines manufacturing in San Diego with key third‑party suppliers, a growing international footprint with more direct sales, and a sizeable patent portfolio. It also details significant risks, including a $1.3 billion accumulated deficit, dependence on pump sales, competitive pressure from large diabetes technology companies and GLP‑1 drug uptake, reimbursement and regulatory uncertainty, cybersecurity and data‑privacy obligations, and the need to service Convertible Senior Notes due 2029.
Tandem Diabetes Care reported record fourth-quarter 2025 results, with worldwide sales of $290.4 million and pump shipments of 38,000. GAAP gross margin reached a record 58%, generating operating income of $8.3 million, while net loss for the quarter was a modest $0.6 million.
For full-year 2025, worldwide sales rose to $1.015 billion, up 12% on a non-GAAP basis, with more than 126,000 pumps shipped and gross margin expanding to 54%. However, GAAP net loss widened to $204.7 million and adjusted EBITDA was negative $46.1 million, pressured by a $75.2 million acquired in-process R&D charge and other costs.
For 2026, the company guides sales to $1.065–$1.085 billion, gross margin of 56–57%, and adjusted EBITDA margin of 5–6%. Guidance reflects a U.S. transition to a pay-as-you-go pharmacy model and direct international operations, including an estimated $70–$80 million sales headwind from the new U.S. model.
ArrowMark Colorado Holdings, LLC filed an amended Schedule 13G to report its passive ownership in DIABETES CARE INC common stock. As of the event date of 12/31/2025, ArrowMark reported beneficial ownership of 2,889,691 shares, representing 4.26% of the outstanding common stock.
ArrowMark, a Delaware entity, disclosed sole voting and dispositive power over all of these shares and no shared power with other parties. It certified that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported routine equity compensation activity. On 01/15/2026, 3,636 restricted stock units were converted into an equal number of common shares at an exercise price of $0. Of these, 2,118 shares were withheld by Tandem Diabetes Care to satisfy tax withholding obligations at $21.07 per share, and no shares were sold into the market. Following these transactions, Kyrillos directly held 24,062 shares of common stock and 21,817 restricted stock units, all under the company’s 2023 Long-Term Incentive Plan.
Tandem Diabetes Care Inc. executive vice president and chief commercial officer Mark D. Novara reported equity activity involving company stock. On 12/15/2025, 7,415 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units granted under the 2023 Long-Term Incentive Plan. To cover tax withholding on this vesting, 3,843 shares were withheld by the company at a price of $22.11 per share, and no shares were sold into the market.
After these transactions, Novara directly beneficially owned 35,956 shares of Tandem Diabetes Care common stock and 29,658 restricted stock units, each representing a contingent right to receive one share of common stock or cash, in accordance with the plan’s terms.
Tandem Diabetes Care Inc. reported an insider equity transaction by its Chief Technology Officer, Rick A. Carpenter. On 12/15/2025, 406 restricted stock units (RSUs) granted on 12/15/2021 under the company’s 2013 Stock Incentive Plan were converted into common stock at an exercise price of $0.
To cover tax withholding on the RSU vesting, the company withheld 207 shares at a price of $22.11 per share, and no shares were sold on the open market. After these transactions, Carpenter directly holds 24,252 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care, Inc. (TNDM) reported an equity award to one of its directors on a Form 4. The director received 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.
Each RSU represents a right to receive either one share of Tandem’s common stock or cash, at the company’s discretion, subject to the plan’s terms. The RSUs vest as to 33% of the total award on November 15, 2026, with the remaining units vesting in two equal annual installments after that date, contingent on the applicable conditions being met.